### Express Mail No. **EV 841 454 541 US**

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palese et al. Confirmation No.: 4596

Application No.: 10/724,273 Group Art Unit: 1648

Filed: November 24, 2003 Examiner: Parkin, Jeffrey S.

For: IDENTIFICATION AND USE OF Attorney Docket No.: 6923-119

ANTIVIRAL COMPOUNDS THAT

INHIBIT INTERACTION OF HOST CELL PROTEINS AND VIRAL PROTEINS REQUIRED FOR VIRAL REPLICATION

#### **AMENDMENT FEE TRANSMITTAL**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

The claim amendment fee has been estimated as shown below:

(Col. 1) CLAIMS REMAINING AFTER AMENDMENT			(Col. 2) HIGHEST NO. PREVIOUSLY PAID	PRESENT EXTRA	SMALL ENTITY			OTHER THAN A SMALL ENTITY			
					RATE	ADDIT. FEE		OR	RATE		ADDIT. FEE
TOTAL	21	MINUS	31	0	x 25	S	0.00		x 50	\$	.00
INDEP.	4	MINUS	7	0	x 100	\$			x 200	\$	0.00
☐ FIRST	FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						0.00			\$	0.00
					TOTAL	\$	0.00	OR	TOTAL	\$	.00

Please charge any required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: October 1, 2007

Laura A. Coruzzi

30,742 (Reg. No.)

By:

Sumber S. Chhed.
Jennifer J. Chheda

(Reg. No.)

**JONES DAY** 

222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosure

OTPE TEAM OF THE T

10-03-07

Express Mail No. <u>EV 841 454 541 US</u>

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palese et al.

Confirmation No.: 4596

Application No.: 10/724,273

Group Art Unit: 1648

Filed: November 24, 2003

Examiner: Parkin, Jeffrey S.

For: IDENTIFICATION AND USE OF

Attorney Docket No.: 6923-119

ANTIVIRAL COMPOUNDS THAT
INHIBIT INTERACTION OF HOST CELL
PROTEINS AND VIRAL PROTEINS

PROTEINS AND VIRAL PROTEINS REQUIRED FOR VIRAL REPLICATION

## AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed May 31, 2007 ("Office Action"), and in accordance with 37 C.F.R. § 1.111, please consider the amendments and remarks set forth below in connection with the above-identified patent application. Applicants submit concurrently herewith: (1) a Petition for Extension of Time Under 37 C.F.R. § 1.136(a) for one month from August 31, 2007 up to and including September 30, 2007 with a provision authorizing payment of the required fee (in duplicate); (2) an Amendment Fee Transmittal with a provision authorizing payment of the required claim amendment fees (in duplicate); (3) a Substitute Specification and a marked-up version of the Substitute Specification, pursuant to 37 C.F.R. §§ 1.121(a)(3) and 1.125 (b) and (c); (4) a copy of the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated May 29, 2007; (5) a paper form of a Substitute Sequence Listing pursuant to 37 C.F.R. §§ 1.821-1.825; (6) a Computer Readable Form (CRF) of the Substitute Sequence Listing pursuant to 37 C.F.R. §§ 1.821-1.825; and (7) an Information Disclosure Statement Under 37 C.F.R. § 1.56 and § 1.97 (in duplicate) with an accompanying revised form PTO 1449 (List of References Cited By Applicants) and copies of References A09, B01-B03 and C66-C162.

Amendments to the Specification begin on page 3 of this paper

Amendments to the Claims begin on page 4 of this paper.

Remarks begin on page 7 of this paper.